KRAS and hematopoietic and lymphoid system neoplasm: To better compare RAS protein stability between different tumor types, we used cycloheximide to track RAS protein levels in diverse cell lines which all harbored mutant KRAS, including adenocarcinoma lines from colon (COAD; LOVO and GP2D; blue) and pancreas (PAAD; ASPC1 and PANC1; black), as well as additional blood cancer lines from germinal center B cell diffuse large B cell lymphoma (GCB DLBCL) (WSU-FSCCL, Toledo, and WILL2; orange) and AML (HL60 and THP1; red).